Vulnerability Details : CVE-2019-15931
Intesync Solismed 3.3sp allows Directory Traversal, a different vulnerability than CVE-2019-16246.
Vulnerability category: Directory traversal
Products affected by CVE-2019-15931
- cpe:2.3:a:intesync:solismed:3.3:sp1:*:*:*:*:*:*
Exploit prediction scoring system (EPSS) score for CVE-2019-15931
0.43%
Probability of exploitation activity in the next 30 days
EPSS Score History
~ 75 %
Percentile, the proportion of vulnerabilities that are scored at or less
CVSS scores for CVE-2019-15931
Base Score | Base Severity | CVSS Vector | Exploitability Score | Impact Score | Score Source | First Seen |
---|---|---|---|---|---|---|
7.5
|
HIGH | AV:N/AC:L/Au:N/C:P/I:P/A:P |
10.0
|
6.4
|
NIST | |
9.8
|
CRITICAL | CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H |
3.9
|
5.9
|
NIST |
CWE ids for CVE-2019-15931
-
The product uses external input to construct a pathname that is intended to identify a file or directory that is located underneath a restricted parent directory, but the product does not properly neutralize special elements within the pathname that can cause the pathname to resolve to a location that is outside of the restricted directory.Assigned by: nvd@nist.gov (Primary)
References for CVE-2019-15931
-
https://www.solismed.com/
Solismed Clinic Management SystemProduct
-
https://www.bishopfox.com/blog/news-category/advisories/
Bishop Fox AdvisoriesThird Party Advisory
-
https://know.bishopfox.com/advisories/solismed-critical
Solismed Version 3.3SP1Exploit;Third Party Advisory
-
https://bishopfox.com
Bishop FoxThird Party Advisory
Jump to